Let's be careful. The autophagy paper cited makes no mention of the S1 receptor. S1 may play a role but that play has a big cast. It is very easy and tempting to overhype an experimental drug and its MOA as the star of every show. It happens with most of them, see other biotechs and their hype.
We have clinical results coming up for PDD. Look for data signal that will justify a phase 3. It's very exciting.
Thank you for the excellent posts today. Chock full of great information regarding our drug and backed up by publications of research regarding the MoA of our drug as stated by the company and validated by third party objective/neutral researchers in the field.
Top notch! Your effort is a lighthouse for investors to steer by and avoid the rocks.
Much appreciated insight meticulously supported with the links which nail down the facts.
Commendation for your foundational posts and Thank you for your service.
News 
Market Data 
Discover 
